Stockscreener 앱 받기
50.69
1.32%
-0.65
전일 마감가:
$51.34
열려 있는:
$51.37
하루 거래량:
84,627
Relative Volume:
0.12
시가총액:
$2.91B
수익:
$665.13M
순이익/손실:
$64.50M
주가수익비율:
44.30
EPS:
1.1442
순현금흐름:
$185.87M
1주 성능:
+2.61%
1개월 성능:
-1.36%
6개월 성능:
+22.84%
1년 성능:
+29.93%
1일 변동 폭
$49.88
$51.59
1주일 범위
$49.88
$51.99
52주 변동 폭
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
50.72 | 2.94B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.40 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
129.11 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.18 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.94 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
474.59 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 재개 | Jefferies | Buy |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 재개 | Jefferies | Hold |
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-11-12 | 재확인 | B. Riley FBR | Buy |
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
| 2017-10-19 | 개시 | FBR & Co. | Buy |
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 개시 | Janney | Neutral |
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-11-05 | 재확인 | Northland Capital | Outperform |
| 2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Can Supernus Pharmaceuticals Inc. stock sustain institutional interestJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Is Supernus Pharmaceuticals (SUPN) Offering Value After Strong Multi Year Share Price Gains - Sahm
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Lupin launches epilepsy drug in US - ET Pharma
Lupin Launches Topiramate Extended-Release Capsules in the United States - The Malaysian Reserve
(SUPN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Strong results lifted Supernus Pharmaceuticals (SUPN) in Q3 - MSN
India's Lupin Launches Seizure Drug Bioequivalent to Supernus Pharmaceuticals' Trokendi XR - marketscreener.com
Patterns Watch: Should I trade or invest in Supernus Pharmaceuticals Inc2025 Key Highlights & Reliable Price Action Trade Plans - baoquankhu1.vn
SupernusOutlook For 2026 Positive, Upholding Buy Rating (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Buy" at Wall Street Zen - MarketBeat
Published on: 2026-01-31 06:25:45 - baoquankhu1.vn
Supernus Pharmaceuticals amends merger agreement to adjust milestone payments - Investing.com
Supernus Revises Merger Milestone Payment Obligations Agreement - TipRanks
Is Supernus Pharmaceuticals Inc. being accumulated by smart moneyJuly 2025 Patterns & Fast Exit and Entry Trade Guides - mfd.ru
Published on: 2026-01-28 12:01:32 - baoquankhu1.vn
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Exploring a 24.76% Potential Upside - DirectorsTalk Interviews
Analysis Recap: Should you avoid Supernus Pharmaceuticals Inc. stock right nowWeekly Trade Analysis & Risk Managed Trade Strategies - baoquankhu1.vn
Price-Driven Insight from (SUPN) for Rule-Based Strategy - Stock Traders Daily
Recent 3.5% pullback isn't enough to hurt long-term Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders, they're still up 64% over 5 years - simplywall.st
Loss Report: Is Supernus Pharmaceuticals Inc stock forming a triangle pattern2025 Buyback Activity & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Supernus Pharmaceuticals (SUPN) Stock Analysis: Exploring A 22.67% Potential Upside - DirectorsTalk Interviews
Chart Watch: Is Supernus Pharmaceuticals Inc a stock for growth or value investorsRate Cut & Weekly Sector Rotation Insights - baoquankhu1.vn
Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) t - GuruFocus
Investment Review: Should you avoid Supernus Pharmaceuticals Inc stock right now2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
(SUPN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? - MSN
How Supernus Pharmaceuticals Inc. stock performs after earningsJuly 2025 Pullbacks & Comprehensive Market Scan Insights - Улправда
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cantor Fitzgerald reiterates Overweight rating on Supernus Pharmaceuticals stock By Investing.com - Investing.com UK
Will Supernus Pharmaceuticals Inc. stock deliver long term returnsEarnings Performance Report & Verified Swing Trading Watchlist - Улправда
Why retail investors pile into Supernus Pharmaceuticals Inc. stockJuly 2025 Drop Watch & Technical Buy Zone Confirmation - Улправда
Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance
Investment Recap: How Supernus Pharmaceuticals Inc stock compares to growth peersProduct Launch & Weekly High Momentum Picks - Bộ Nội Vụ
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Unlocking a 24% Potential Upside in the CNS Market - DirectorsTalk Interviews
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
(SUPN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Supernus Pharmaceuticals Earnings Notes - Trefis
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Rice Hall James & Associates LLC Has $22.75 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
SUPN (Supernus Pharmaceuticals) EV-to-OCF : 37.98 (As of Dec. 25, 2025) - GuruFocus
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Insider Sold Shares Worth $1,008,150, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) SVP Sells 20,000 Shares of Stock - MarketBeat
Supernus Pharmaceuticals Senior VP Sells Shares - TradingView — Track All Markets
Supernus Pharmaceuticals (SUPN) Is Up 6.0% After FDA Approval Of ONAPGO Parkinson’s DrugHas The Bull Case Changed? - Sahm
Optimism flows from pot to psychedelics: Atai Beckley, Supernus stocks rise after analyst flags positive tailwinds from Trump’s marijuana order - MSN
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order - Stocktwits
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Dec 19 '25 |
Option Exercise |
28.82 |
20,000 |
576,500 |
30,496 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Dec 19 '25 |
Sale |
50.41 |
20,000 |
1,008,150 |
15,496 |
0.04%
9.18%
자본화:
|
볼륨(24시간):